A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Recruiting · NCT07017725 · Registry updated 2025-06-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia | Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, blood coagulation disease, hematologic disorder, purpura | Recruiting | Phase 1 / Phase 2 | 2025-06-12 | NCT07017725 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CASI pharmaceuticals, Inc. | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Henan Cancer Hospital | Zhengzhou | China | 76 |
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin | China | 3 |
| North China University of Science and Technology Affiliated Hospital | Tangshan | China | 7 |
| Qilu Hospital of Shandong University | Jinan | China | 1 |
| The First Affiliated Hospital of Nanchang University | Nanchang | China | 18 |
| The Second Affiliated Hospital of Kunming Medical University | Kunming | China | 5 |